Improved durable responses regardless of age following cytoreduction and “no-tourniquet” hyperthermic isolated limb chemotherapy for in transit melanoma of the extremity.

ConclusionCombining cytoreduction with no-tourniquet HILP/HILI for in-transit metastatic melanoma of the extremity resulted in 100% survival regardless of age at 1 year and 68% 3-year survival in patients over 80 without any increase in adverse events.
Source: The American Journal of Surgery - Category: Surgery Source Type: research